Published in Drug Law Weekly, June 2nd, 2009
Under the terms of the agreement, which closed today, Biovail has paid $510 million to GSK to acquire the full U.S. rights to Wellbutrin XL®.
Wellbutrin XL® is indicated for the treatment of major depressive disorder and seasonal affective disorder. About Biovail Corporation Biovail Corporation is a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.